These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2587438)

  • 1. A possible mechanism of tumor regression in cisplatin-treated mice.
    Sarna S; Sodhi A; Bhola RK
    Pol J Pharmacol Pharm; 1989; 41(1):69-76. PubMed ID: 2587438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced cell mediated immunity in mice after cisplatin treatment.
    Bahadur A; Sarna S; Sodhi A
    Pol J Pharmacol Pharm; 1984; 36(5):441-8. PubMed ID: 6543466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive transfer of immunity against solid fibrosarcoma in mice with splenocytes and peritoneal exudate cells obtained after in vitro sensitization and in vivo immunization with cis-dichlorodiamine platinum(II) treated fibrosarcoma cells.
    Sodhi A; Tandon P; Sarna S
    Arch Geschwulstforsch; 1985; 55(1):47-61. PubMed ID: 3872651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice.
    Fujii T; Igarashi T; Kishimoto S
    J Natl Cancer Inst; 1987 Mar; 78(3):509-17. PubMed ID: 2950265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of cell mediated immunity in vitro and in vivo after cis-platin treatment.
    Bahadur A; Sodhi A
    Pol J Pharmacol Pharm; 1985; 37(4):453-61. PubMed ID: 4080642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody-based mechanism for tumor immunity.
    Bright RK; Shearer MH; Kennedy RC
    J Immunol; 1994 Sep; 153(5):2064-71. PubMed ID: 8051411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
    Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
    J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the involvement of cells from donor and recipient mice in adoptive transfer of antitumor immunity.
    Lee FH; Currie D; Hwang KM
    Cancer Res; 1984 Dec; 44(12 Pt 1):5491-8. PubMed ID: 6208997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased cytotoxic sensitivity of YPC-1 tumor cells from mice treated with nitrosoureas.
    Hunyadi J; Szegedi G; Szabo T; Ahmed A; Laki K
    Cancer Res; 1981 May; 41(5):1677-81. PubMed ID: 6111391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of macrophages in tumour immunity. I. Co-operation between macrophages and lymphoid cells in syngeneic tumour immunity.
    Evans R; Alexander P
    Immunology; 1972 Oct; 23(4):615-26. PubMed ID: 5084104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of macrophage function by 2-chloroadenosine.
    Ohtani A; Kumazawa Y; Fujisawa H; Nishimura C
    J Reticuloendothel Soc; 1982 Sep; 32(3):189-200. PubMed ID: 7153986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage-mediated, antibody-dependent destruction of tumor cells in DBA/2 mice: in vitro identification of an in situ mechanism.
    Key M; Haskill S
    J Natl Cancer Inst; 1981 Jan; 66(1):103-10. PubMed ID: 7005500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enrichment of antitumor effector cells that are effective in vivo from spleen cells of tumor-bearing mice through the use of Dolichos biflorus lectin.
    Okada T; Ezawa K; Imai Y; Osawa T
    Cancer Res; 1986 Nov; 46(11):5611-7. PubMed ID: 3093067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.
    Gorelik L; Rubin M; Prokhorova A; Mokyr MB
    J Immunol; 1995 Apr; 154(8):3941-51. PubMed ID: 7706732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor cell-triggered macrophage-mediated suppression of the T-cell cytotoxic response to tumor-associated antigens. I. Characterization of the cell components for induction of suppression.
    Ting CC; Rodrigues D
    J Natl Cancer Inst; 1982 Oct; 69(4):867-72. PubMed ID: 6214653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophage-mediated natural cytotoxicity of dimethyl sulfoxide-treated Friend erythroleukemia cells.
    Hsu KH; Friedman H
    J Natl Cancer Inst; 1985 Jul; 75(1):105-10. PubMed ID: 3859684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
    Bartik MM; Takesue BY; Mokyr MB
    Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for cytostatic T cell activity in the effector mechanism against syngeneic TMT mammary tumor cells in mice.
    Kurata S; Tsuchiya T; Norimura T; Yamashita U
    J Immunol; 1983 Jan; 130(1):496-500. PubMed ID: 6600195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoimmunotherapeutical studies on Dalton's lymphoma with cis-platin.
    Bahadur A
    Pol J Pharmacol Pharm; 1985; 37(4):463-8. PubMed ID: 4080643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the mechanism of allograft rejection and cell-mediated immunity. II. Divergent effect of CY pretreatment on the generation of cytotoxic activity in the draining lymph nodes and spleen.
    Nanishi F; Taniguchi K; Kubo C; Onoyama K; Omae T; Nomoto K
    J Clin Lab Immunol; 1983 Sep; 12(1):23-30. PubMed ID: 6631941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.